Quarterly report [Sections 13 or 15(d)]

Related Party Transactions

v3.26.3
Related Party Transactions
9 Months Ended
Sep. 30, 2026
Related Party Transactions [Abstract]  
Related Party Transactions

18. Related Party Transactions

 

Accounts payable – related party

 

As of September 30, 2026 and December 31, 2025, the Company had outstanding balances of $450 thousand and $456 thousand, respectively, due to C.G. Laboratories, Inc., a related party. Additionally, as of September 30, 2026 and December 31, 2025, the Company had an outstanding balance of $8 thousand and $17 thousand, respectively, to the CEO of CG Labs. These balances primarily relate to transactions for contract manufacturing, packaging, and other services provided by CG Laboratories, Inc.

 

Brian J. Kieser, the Company’s Interim Chief Executive Officer since August 21, 2026 and a member of its Board of Directors, is the Chief Executive Officer and sole owner of Sequence LifeScience, Inc. (“Sequence”). On April 17, 2026, prior to Mr. Kieser’s appointment to the Company’s Board of Directors, Sequence purchased an unsecured convertible promissory note in the original principal amount of $5.5 million, convertible into up to 458,333 shares of common stock, and a warrant to purchase up to 229,167 shares of common stock, in each case on the same terms as those issued to the other buyers in the private placement described in Note 13. Mr. Kieser was appointed to the Company’s Board of Directors on May 6, 2026. On May 11, 2026, following his appointment to the Board, Mr. Kieser personally purchased an additional unsecured convertible promissory note in the original principal amount of $1 million, convertible into up to 83,333 shares of common stock, and a warrant to purchase up to 41,667 shares of common stock, on the same terms as those issued to the other buyers in that offering. As of September 30, 2026, the aggregate principal amount outstanding under the notes held by Sequence and Mr. Kieser was $6.5 million.

 

 

Sales Representative Obligations

 

In connection with the Company’s April 2026 transaction with Celularity Inc., the Company assumed obligations to two sales representatives. On September 10, 2026, Sequence issued promissory notes directly to the sales representatives in the principal amounts of $804,625 and $292,750, each guaranteed by Mr. Kieser, and paid $100,000 to one representative., in each case in satisfaction of the Company’s obligations to the sales representatives. Under an Accommodation and Reimbursement Agreement dated as of September 10, 2026 and approved by the Company’s Audit Committee and Board of Directors on October 14, 2026, with an interested director recused, the Company will reimburse Sequence and Mr. Kieser for amounts they actually pay on these obligations, including principal, interest and extension fees, and the $100,000 payment. The reimbursement obligation does not itself bear interest. The Company remains the primary obligor to the sales representatives, has agreed to indemnify the sales representatives if Sequence or Mr. Kieser fails to pay its note, and continues to record the obligations to the sales representatives, including the $100,000 payment, as liabilities of $1,097 thousand as of September 30, 2026.